Calidi Biotherapeutics Debuts as a Publicly Traded Company Focused on Arming the Immune System to Fight Cancer with a New Generation of Targeted Immunotherapies Business combination transaction with First Light Acquisition Group, a special purpose acquisition company, completed on September 12, 2023 Gross proceeds made available to Calidi Biotherapeutics...

First Light Acquisition Group Announces NYSE Approval for Listing of Business Combination with Calidi Biotherapeutics and Additional New Capital Commitments Business combination transaction with Calidi Biotherapeutics anticipated to be completed on September 12, 2023 Gross proceeds made available to Calidi Biotherapeutics from transaction will total...